Senna and carcinogenicity
This article was originally published in The Tan Sheet
Executive Summary
Purdue Pharma will amend and submit its final report on a two-year oral carcinogenicity study in rats to support the safety of senna-containing OTC laxatives by end of March 2004, company states in recent letter to FDA. Agency requested the completion of histopathological examinations of the brain tissues from the remaining animals of the low- and mid-dose groups in an Oct. 21. letter to the company. Purdue will evaluate 33 rats in its follow up examination. "It must be noted that the protocol for this study was reviewed and accepted by the Carcinogenicity Assessment Committee [and] this additional analysis was not required according to the protocol," Purdue states in the letter...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.